CTOs on the Move

Viracta

www.viracta.com

 
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.viracta.com
  • 2533 South Coast Highway 101 Suite 210
    Cardiff, CA USA 92007
  • Phone: 858.400.8470

Executives

Name Title Contact Details

Funding

Viracta raised $10M on 12/04/2018
Viracta raised $65M on 02/24/2021
Viracta raised $50M on 11/05/2021

Similar Companies

Egenomics

Egenomics is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.

AMPAC Fine Chemicals

AMPAC Fine Chemicals (AFC) manufactures active pharmaceutical ingredients (APIs) and registered intermediates for customers in the pharmaceutical industry. Our integrated facilities are located in Rancho Cordova, California, approximately 20 miles east

Curran Biotech

Curran Biotech is a materials manufacturing company that provides nano coatings to biochemical, chemical, energy and construction industries including water-repellent coatings for fabrics, canvas, tarps, and glass. Our hydrophobic coatings are specifically designed to improve the nature and quality of the substrates by preventing water-substrate interactions. The technology was developed in the materials/chemistry labs (Institute for Nano Energy) of the physics department at the University of Houston and started commercialization in 2013.